ARS Pharma Reports Q4 Revenue of $28.1M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy SPRY?
Reports Q4 revenue $28.1M, consensus $25.58M. "2025 was an important year for ARS Pharma as we established neffy as a differentiated, scalable epinephrine treatment of choice. We have built a strong base business with initial prescriptions expected to begin renewing in 2026 as product reaches expiration. This shift towards renewals, combined with continued growth in new neffy patients, positions us to accelerate market share expansion," said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPRY
Wall Street analysts forecast SPRY stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.560
Low
30.00
Averages
32.50
High
35.00
Current: 8.560
Low
30.00
Averages
32.50
High
35.00
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ARS Pharma Updates neffy Dosage Guidelines for All Weights
- Removal of Age Restrictions: The FDA has approved an update to the prescribing information for neffy® 1 mg, eliminating age restrictions for children, allowing all individuals weighing ≥33 lbs to access this needle-free epinephrine, significantly enhancing emergency treatment options for allergic reactions, particularly for children under four.
- Increased Portability: The updated labeling recommends that patients store neffy in blister packaging or a dedicated carrying case, with ARS Pharma set to include a carrying case with each prescription starting this summer, aimed at improving convenience and confidence for patients during emergencies.
- Market Demand Response: Approximately 25% of patients requiring epinephrine are children weighing ≥33 lbs and <66 lbs, with about 25% being under four years old; the updated guidelines will effectively reduce barriers for parents in emergency situations, enhancing the product's market competitiveness.
- Enhanced Safety: The FDA also updated flexible guidance on using neffy, allowing for use after accidental freezing and at high temperatures (up to 122°F), further improving the product's applicability and safety, meeting patient needs across various environments.
See More
FDA Allows ARS Pharmaceuticals to Remove Age Requirement for Neffy
- Age Requirement Removal: The FDA's approval for ARS Pharmaceuticals to eliminate the age requirement for neffy (epinephrine nasal spray) allows children and adults weighing at least 33 pounds (approximately 15 kg) to use the product, thereby expanding the potential user base and enhancing market acceptance.
- Labeling Update: The labeling change includes more flexible guidance regarding the administration of the medication, temperature excursions, and freezing conditions, aimed at improving usability and safety, thus enhancing the user experience.
- Sales Strategy Adjustment: ARS Pharmaceuticals is expanding its sales force and implementing a digital strategy to drive neffy sales growth while maintaining SG&A expenses in 2026, demonstrating the company's confidence in future market potential.
- Optimistic Market Outlook: With the gradual increase in neffy sales and global expansion, ARS Pharmaceuticals is positioned for a potential re-rating of its stock, attracting more investor attention and further driving company growth.
See More
ARS Pharmaceuticals Receives FDA Approval for neffy Label Update
- FDA Approval Update: ARS Pharmaceuticals announced that the U.S. FDA has approved an update to the prescribing information for neffy 1 mg epinephrine nasal spray, removing age restrictions and allowing all children and adults weighing 33 lbs. or more to use it, significantly broadening the drug's eligible user base.
- Increased Accessibility: The label update not only lowers treatment hurdles but also encourages patients to carry neffy in its blister packaging or carrying case, ensuring rapid access during emergencies, thereby enhancing the response capability to Type 1 allergic reactions and anaphylaxis.
- Expert Commentary: Allergy/Immunology and Pediatrics expert Nicole Chase stated that having a needle-free epinephrine treatment available is an important step forward, helping more patients and caregivers alleviate treatment barriers while protecting children.
- Stock Price Reaction: ARS Pharmaceuticals shares were trading at $8.56 at the last close, up 8.35%, reflecting a positive market response to the FDA approval news, which may further drive the company's market share in the allergy treatment sector.
See More
ARS Pharmaceuticals Q4 2025 Earnings Call Insights
- Significant Revenue Growth: ARS Pharmaceuticals reported total revenue of $84.3 million for 2025, with U.S. net product revenue at $72.2 million, indicating strong performance in new markets and potential for future market share expansion.
- Sales Team Expansion Plan: The company plans to increase its sales force from 106 to 150 in Q2 2026, funded through the reallocation of existing resources, ensuring no increase in SG&A expenses for 2026 while enhancing engagement with priority accounts.
- Improved Market Coverage: By the end of 2025, ARS achieved approximately 93% overall commercial coverage, with 57% of covered lives having access without prior authorization, which is expected to drive sales growth and improve customer satisfaction.
- International Market Expansion: ARS Pharmaceuticals has secured regulatory approvals in Europe, China, Japan, and Australia, with plans for further product launches in 2026, demonstrating its strategic commitment to global expansion.
See More
ARS Pharmaceuticals Reports $84.3 Million Revenue for 2025
- Financial Performance: ARS Pharmaceuticals reported total revenue of $84.3 million for 2025, with $72.2 million from U.S. neffy sales, indicating strong growth potential in the allergy treatment market while reflecting ongoing investment in product promotion.
- R&D Expenses: The company incurred $13.2 million in R&D expenses for 2025, primarily for product development and clinical trials, which, despite being high, underscores its commitment to innovation to enhance market competitiveness.
- Marketing Strategy: ARS plans to maintain a similar annual spend level on neffy promotion in 2026, anticipating that increased patient and caregiver engagement will accelerate market share growth, particularly driven by new advertising campaigns.
- Cash Flow Position: As of December 31, 2025, ARS had $245 million in cash and short-term investments, which is expected to fund operations until cash-flow break-even, demonstrating the company's financial stability.
See More
ARS Pharmaceuticals Reports FY EPS Beat with Strong Cash Position
- Earnings Highlights: ARS Pharmaceuticals reported a FY GAAP EPS of -$1.74, beating expectations by $0.02, while revenue of $84.28 million, down 5.5% year-over-year, still exceeded forecasts by $2.6 million, demonstrating the company's resilience in challenging conditions.
- Cash Position: As of December 31, 2025, ARS Pharma had cash, cash equivalents, and short-term investments totaling $245 million, with 99,290,926 shares outstanding, indicating strong financial management and liquidity.
- Operational Funding Assurance: The company believes its year-end cash position will fund operations through expected cash-flow break-even, providing a solid foundation for future business development and enhancing investor confidence.
- Market Outlook: With climbing Neffy sales and global expansion, ARS Pharmaceuticals' stock could be re-rated, as market interest in its future growth potential continues to rise.
See More
ARS Pharma Updates neffy Dosage Guidelines for All Weights
- Removal of Age Restrictions: The FDA has approved an update to the prescribing information for neffy® 1 mg, eliminating age restrictions for children, allowing all individuals weighing ≥33 lbs to access this needle-free epinephrine, significantly enhancing emergency treatment options for allergic reactions, particularly for children under four.
- Increased Portability: The updated labeling recommends that patients store neffy in blister packaging or a dedicated carrying case, with ARS Pharma set to include a carrying case with each prescription starting this summer, aimed at improving convenience and confidence for patients during emergencies.
- Market Demand Response: Approximately 25% of patients requiring epinephrine are children weighing ≥33 lbs and <66 lbs, with about 25% being under four years old; the updated guidelines will effectively reduce barriers for parents in emergency situations, enhancing the product's market competitiveness.
- Enhanced Safety: The FDA also updated flexible guidance on using neffy, allowing for use after accidental freezing and at high temperatures (up to 122°F), further improving the product's applicability and safety, meeting patient needs across various environments.
See More
FDA Allows ARS Pharmaceuticals to Remove Age Requirement for Neffy
- Age Requirement Removal: The FDA's approval for ARS Pharmaceuticals to eliminate the age requirement for neffy (epinephrine nasal spray) allows children and adults weighing at least 33 pounds (approximately 15 kg) to use the product, thereby expanding the potential user base and enhancing market acceptance.
- Labeling Update: The labeling change includes more flexible guidance regarding the administration of the medication, temperature excursions, and freezing conditions, aimed at improving usability and safety, thus enhancing the user experience.
- Sales Strategy Adjustment: ARS Pharmaceuticals is expanding its sales force and implementing a digital strategy to drive neffy sales growth while maintaining SG&A expenses in 2026, demonstrating the company's confidence in future market potential.
- Optimistic Market Outlook: With the gradual increase in neffy sales and global expansion, ARS Pharmaceuticals is positioned for a potential re-rating of its stock, attracting more investor attention and further driving company growth.
See More
ARS Pharmaceuticals Receives FDA Approval for neffy Label Update
- FDA Approval Update: ARS Pharmaceuticals announced that the U.S. FDA has approved an update to the prescribing information for neffy 1 mg epinephrine nasal spray, removing age restrictions and allowing all children and adults weighing 33 lbs. or more to use it, significantly broadening the drug's eligible user base.
- Increased Accessibility: The label update not only lowers treatment hurdles but also encourages patients to carry neffy in its blister packaging or carrying case, ensuring rapid access during emergencies, thereby enhancing the response capability to Type 1 allergic reactions and anaphylaxis.
- Expert Commentary: Allergy/Immunology and Pediatrics expert Nicole Chase stated that having a needle-free epinephrine treatment available is an important step forward, helping more patients and caregivers alleviate treatment barriers while protecting children.
- Stock Price Reaction: ARS Pharmaceuticals shares were trading at $8.56 at the last close, up 8.35%, reflecting a positive market response to the FDA approval news, which may further drive the company's market share in the allergy treatment sector.
See More
ARS Pharmaceuticals Q4 2025 Earnings Call Insights
- Significant Revenue Growth: ARS Pharmaceuticals reported total revenue of $84.3 million for 2025, with U.S. net product revenue at $72.2 million, indicating strong performance in new markets and potential for future market share expansion.
- Sales Team Expansion Plan: The company plans to increase its sales force from 106 to 150 in Q2 2026, funded through the reallocation of existing resources, ensuring no increase in SG&A expenses for 2026 while enhancing engagement with priority accounts.
- Improved Market Coverage: By the end of 2025, ARS achieved approximately 93% overall commercial coverage, with 57% of covered lives having access without prior authorization, which is expected to drive sales growth and improve customer satisfaction.
- International Market Expansion: ARS Pharmaceuticals has secured regulatory approvals in Europe, China, Japan, and Australia, with plans for further product launches in 2026, demonstrating its strategic commitment to global expansion.
See More
ARS Pharmaceuticals Reports $84.3 Million Revenue for 2025
- Financial Performance: ARS Pharmaceuticals reported total revenue of $84.3 million for 2025, with $72.2 million from U.S. neffy sales, indicating strong growth potential in the allergy treatment market while reflecting ongoing investment in product promotion.
- R&D Expenses: The company incurred $13.2 million in R&D expenses for 2025, primarily for product development and clinical trials, which, despite being high, underscores its commitment to innovation to enhance market competitiveness.
- Marketing Strategy: ARS plans to maintain a similar annual spend level on neffy promotion in 2026, anticipating that increased patient and caregiver engagement will accelerate market share growth, particularly driven by new advertising campaigns.
- Cash Flow Position: As of December 31, 2025, ARS had $245 million in cash and short-term investments, which is expected to fund operations until cash-flow break-even, demonstrating the company's financial stability.
See More
ARS Pharmaceuticals Reports FY EPS Beat with Strong Cash Position
- Earnings Highlights: ARS Pharmaceuticals reported a FY GAAP EPS of -$1.74, beating expectations by $0.02, while revenue of $84.28 million, down 5.5% year-over-year, still exceeded forecasts by $2.6 million, demonstrating the company's resilience in challenging conditions.
- Cash Position: As of December 31, 2025, ARS Pharma had cash, cash equivalents, and short-term investments totaling $245 million, with 99,290,926 shares outstanding, indicating strong financial management and liquidity.
- Operational Funding Assurance: The company believes its year-end cash position will fund operations through expected cash-flow break-even, providing a solid foundation for future business development and enhancing investor confidence.
- Market Outlook: With climbing Neffy sales and global expansion, ARS Pharmaceuticals' stock could be re-rated, as market interest in its future growth potential continues to rise.
See More
